NEW HAVEN, Conn.--Genaissance Pharmaceuticals, a company that exploits gene variation for the pharmaceutical industry, named Joel Claiborne Stephens as director of population genomics. Stephens, who has headed the bioinformatics group at the US National Cancer Institute since 1990, will direct the application of gene haplotypes for more effective clinical trails and the enhancement of drugs in the market, Genaissance said.